Ngā hua rapu - Marielle Pluyter
- E whakaatu ana i te 1 - 2 hua o te 2
-
1
Estimation of dose requirements for sustained <i>in vivo</i> activity of a therapeutic human anti‐CD20 antibody mā Wim K. Bleeker, Martin E. Munk, Wendy J.M. Mackus, Jeroen H. N. van den Brakel, Marielle Pluyter, Martin J. Glennie, Jan G. J. van de Winkel, Paul W.H.I. Parren
I whakaputaina 2007Artigo -
2
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy mā Wim K. Bleeker, Jeroen J. Lammerts van Bueren, Heidi H. van Ojik, Arnout F. Gerritsen, Marielle Pluyter, Mischa Houtkamp, Ed Halk, J. Goldstein, Janine Schuurman, Marc A. van Dijk, Jan G. J. van de Winkel, Paul W.H.I. Parren
I whakaputaina 2004Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Antibody
Biology
Biotechnology
Immunology
In vivo
A431 cells
Antibody-dependent cell-mediated cytotoxicity
Biochemistry
CD20
Cancer research
Cell
Cell cycle
Dosing
Environmental health
Epidermal growth factor
Epidermal growth factor receptor
Ex vivo
Immune system
Immunotherapy
Medicine
Molecular biology
Molecular medicine
Monoclonal antibody
Ofatumumab
Pharmacokinetics
Pharmacology
Population
Receptor